Ensysce Biosciences (ENSC)
NASDAQ:ENSC
Want to see ENSC full AI Analyst Report?
ENSC Stock Chart & Stats
$1.01
-$0.28(-3.41%)
At close: 4:00 PM EST
$1.01
-$0.28(-3.41%)
Day’s Range― - ―
52-Week Range$0.23 - $2.75
Previous CloseN/A
Volume52.20K
Average Volume (3M)89.63K
Market Cap
$4.19M
Enterprise Value$2.00M
Total Cash (Recent Filing)$745.48K
Total Debt (Recent Filing)$245.85K
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Aug 19, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.35
Shares Outstanding15,365,530
10 Day Avg. Volume106,568
30 Day Avg. Volume89,627
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.46
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue1.38
Enterprise Value/Gross Profit-1.33
Enterprise Value/Ebitda-0.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.54
Revenue Forecast (FY)$7.70M
Bulls Say, Bears Say
Bulls Say
Proprietary Abuse-deterrent TechEnsysce's TAAP and MPAR platforms represent durable proprietary assets focused on abuse-deterrent and overdose-protection for opioid analgesics. These technologies create differentiation vs. generic opioids, support regulatory exclusivity and make the company an attractive partner or licensor over multiple development cycles.
Patent Protection ExpansionExpansion of patent protection for MPAR strengthens the firm's intellectual property moat, extending potential exclusivity and reducing competitive encroachment. Stronger IP supports licensing negotiations, partnership leverage and long-term commercial upside for the MPAR program across regulatory and market adoption timelines.
Committed Financing Line And $2M TrancheThe $2M close and access to a committed funding line provide tangible runway to progress clinical TAAP/MPAR studies, reducing near-term solvency risk. Structural access to capital over 24 months increases probability of reaching milestones and de-risks program continuity vs. one-off financings.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flows indicate the company cannot self-fund development and must rely on external financing. Continued cash burn raises execution risk for clinical programs, increases dilution probability, and makes long-term project completion contingent on future capital availability.
Negative Equity / Weak Balance SheetPersistent negative equity signals capitalization stress and reduces financial flexibility. It complicates borrowing, weakens negotiating power with partners, and heightens the chance that future financings will be dilutive or come on restrictive terms, pressuring long-term strategic options.
Dilution And Governance OverhangConvertible preferred stock, warrants and adjustments tied to financings create a credible pathway to sizable dilution as instruments convert or are exercised. Coupled with a board member resignation, this raises governance and shareholder-alignment risks that can affect strategic execution and investor confidence over multiple financing cycles.
Ensysce Biosciences News
ENSC FAQ
What was Ensysce Biosciences’s price range in the past 12 months?
Ensysce Biosciences lowest stock price was $0.23 and its highest was $2.75 in the past 12 months.
What is Ensysce Biosciences’s market cap?
Ensysce Biosciences’s market cap is $4.19M.
When is Ensysce Biosciences’s upcoming earnings report date?
Ensysce Biosciences’s upcoming earnings report date is Aug 19, 2026 which is in 56 days.
How were Ensysce Biosciences’s earnings last quarter?
Ensysce Biosciences released its earnings results on May 18, 2026. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.73 by $0.21.
Is Ensysce Biosciences overvalued?
According to Wall Street analysts Ensysce Biosciences’s price is currently Overvalued.
Does Ensysce Biosciences pay dividends?
Ensysce Biosciences does not currently pay dividends.
What is Ensysce Biosciences’s EPS estimate?
Ensysce Biosciences’s EPS estimate is -0.5.
How many shares outstanding does Ensysce Biosciences have?
Ensysce Biosciences has 15,365,530 shares outstanding.
What happened to Ensysce Biosciences’s price movement after its last earnings report?
Ensysce Biosciences reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.73. Following the earnings report the stock price went up 13.214%.
Which hedge fund is a major shareholder of Ensysce Biosciences?
Currently, no hedge funds are holding shares in ENSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ensysce Biosciences
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Technical Analysis
Ownership Overview
―
Insiders
0.22% Mutual Funds
1.64% Other Institutional Investors
98.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---